Mereo BioPharma Group PLC (LON:MPH) insider Denise Scots-Knight acquired 13,500 shares of the company’s stock in a transaction dated Thursday, September 19th. The shares were purchased at an average cost of GBX 59 ($0.77) per share, with a total value of £7,965 ($10,407.68).
Denise Scots-Knight also recently made the following trade(s):
- On Thursday, August 15th, Denise Scots-Knight acquired 6,000 shares of Mereo BioPharma Group stock. The shares were purchased at an average cost of GBX 54 ($0.71) per share, with a total value of £3,240 ($4,233.63).
- On Thursday, July 18th, Denise Scots-Knight acquired 10,000 shares of Mereo BioPharma Group stock. The shares were purchased at an average cost of GBX 51 ($0.67) per share, with a total value of £5,100 ($6,664.05).
Shares of LON MPH traded up GBX 1 ($0.01) during mid-day trading on Friday, hitting GBX 60.50 ($0.79). 2,721 shares of the stock were exchanged, compared to its average volume of 266. The company has a market cap of $59.27 million and a P/E ratio of -1.34. The stock’s fifty day simple moving average is GBX 50.76 and its two-hundred day simple moving average is GBX 98.99. The company has a debt-to-equity ratio of 65.56, a quick ratio of 2.05 and a current ratio of 2.13. Mereo BioPharma Group PLC has a twelve month low of GBX 40 ($0.52) and a twelve month high of GBX 268 ($3.50).
Mereo BioPharma Group plc, a specialty biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of rare and specialty diseases. Its product candidates include BPS-804, a monoclonal antibody, which is in Phase IIb clinical trial for the treatment of osteogenesis imperfecta; AZD-9668, an oral small molecule that has been completed Phase I clinical trial to treat Alpha-1 antitrypsin deficiency; BGS-649, an oral aromatase inhibitor, which is in Phase IIb clinical trial for the treatment of hypogonadal hypogonadism; and BCT-197, an oral p38 MAP kinase inhibitor that is in Phase II clinical trial to treat acute exacerbations of chronic obstructive pulmonary disease.
Featured Story: How is a management fee different from a performance fee?
Receive News & Ratings for Mereo BioPharma Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mereo BioPharma Group and related companies with MarketBeat.com's FREE daily email newsletter.